Eye implant to dispense ganciclovir data

Results of a Phase II trial of the implant from CHIR's Chiron Vision Corp. unit (Irvine, Calif.) showed elimination of signs of active infection for a median of 226 days, about eight months, in 26 patients with newly diagnosed eye infection.

As published in the Archives of Ophthalmology, 30 eyes were assigned at random to either immediate treatment (14 eyes) or deferred treatment until progression was noted (16 eyes). ...